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Delivery of Oncolytic Reovirus by Cell Carriers 







Oncolytic virus therapy is a rapidly expanding branch of cancer immunotherapy and 
represents a genuine opportunity to improve currently available treatment options.  
However, as single agents oncolytic viruses have shown only moderate clinical benefit and 
many challenges remain before their full potential is realized.  Central to this is the efficient 
delivery of the virus to the tumour site and potentiation of the anti-tumour immune 
response.  This chapter describes the loading of oncolytic reovirus onto monocytes which act 
as carriers for delivery of the virus to the tumour site and, as antigen presenting cells, may 
also thereby potentiate the development of an adaptive anti-tumour immune response. 
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1. Introduction 
Oncolytic viruses (OVs) are those that preferentially infect and lyse tumour cells while 
sparing normal tissues.  They were first developed as direct cytotoxic agents(1-3) but it is 
now known that their anti-tumour activity also depends to a large extent on activation of the 
immune system(4, 5).  The best route of delivery for OVs is not yet known; the route 
designed to maximize oncolysis may not best facilitate immune-mediated tumour clearance.  
As of 2018, the only FDA-approved OV (T-VEC) is administered by direct injection into the 
tumour (melanoma).  This route ensures delivery of the full viral dose to the tumour tissue 
but the degree of anti-tumour immunity generated may be sub-maximal; observed 
responses to T-VEC were 15% in visceral metastases versus 64% in directly injected 
lesions(6).  Perhaps more important, the use of intra-tumoural administration restricts the 
use of OV to those tumours that are readily accessible and many are not.  Systemic delivery 
is safe, broadly applicable in a clinical setting, and more suitable for targeting visceral or 
widespread metastatic disease.  However, virus delivered into the bloodstream faces 
inactivation by several mechanisms including scavenger cells in the blood or 
reticuloendothelial organs and immune molecules such as complement and virus-specific 
antibodies.  Thus the virus faces rapid neutralization before it can ever reach the tumour.  
One method that has been investigated to protect the OV within the bloodstream is to load 
the virus onto or into carrier cells.  Various cell types have demonstrated efficacy as carriers 
for OV delivery to tumours including, transformed cells, endothelial cells and immune 
cells(7-10).  The benefit of using immune cells is the potential for a dual attack on the 
tumour.  For example, using tumour-specific T cells for direct delivery of an oncolytic agent 
theoretically ensures specific delivery of the virus to the tumour target and, in addition, 
benefits from the cytotoxic potential of the carrier cell(11).  Although expanding endogenous 
tumour-specific T cells from patients is still problematic, chimeric antigen receptor (CAR) T 
cells represent an attractive possibility as viral carriers(12).  Alternatively, using antigen 
presenting cells such as dendritic cells (DC) or monocytes as the viral carriers may enhance 
the development of an adaptive anti-tumour immune response(10, 13). 
More recently, it has been shown that virus-specific neutralizing antibodies are not always a 
barrier to systemic OV delivery and tumour therapy.  Reovirus, a non-enveloped, double 
stranded RNA virus, is taken up more efficiently by monocytes in the presence of anti-viral 
antibodies(14); this is dependent on antibody receptors expressed by these cells.  
Furthermore, while antibody-neutralized reovirus or Coxsackievirus are unable to infect and 
kill tumour cells directly, when loaded onto human monocytes these viruses can be 
delivered to tumour cells in a functional/replicative form resulting in cell lysis(15).  The 
protocol for loading monocytes with reovirus or with reovirus-antibody complexes is 
described below.  The same protocol is effective for the loading of other immune cell 
subtypes following their isolation by magnetic-activated cell sorting (MACS); T cells, DC 
and natural killer (NK) cells have all been loaded in this manner.  After viral loading, the 
carrier cells can be co-cultured with tumour targets for 72-96 h to elicit tumour cell death. 
2. Materials 
2.1 Preparation of human cells 
1. Human buffy coat/leukapheresis cone/fresh blood 
2. PBS 
3. Lymphoprep density gradient medium 
4. Pasteur pipettes 
5. human anti-CD14 MicroBeads or the Pan Monocyte isolation kit (see Note 1) 
6. MACS Manual Separator 
7. Magnetic cell separation LS columns 
8. MACS buffer: PBS containing 1% (v/v) FBS and 2mM EDTA 
2.2 Preparation of murine cells 
1. Dissection equipment: scissors, tweezers, scalpel 
2. Sterile 70% ethanol 
3. Complete RPMI: supplement RPMI with 10% (v/v) FBS, 2 mM L-glutamine╇やｰ╆ｰｵやmMやぽ-
mercaptoethanol, Penicillin 100 U/ml, Streptomycin 100 µg/ml. 
4. Mouse monocyte isolation kit (bone marrow) 
5. MACS Manual Separator 
6. Magnetic cell separation LS columns 
7. MACS buffer: PBS containing 1% (v/v) FBS and 2 mM EDTA 
2.3 Loading immune cells with reovirus 
1. Complete medium as required for target cells 
2. Complete RPMI 
3. Reovirus 
4. Anti-reoviral antibodies (optional, for generating antibody-neutralized reovirus 
complexes) 
3. Methods 
3.1 Preparation of cells 
3.1.1 Preparation of human PBMC by density gradient separation 
Carry out all steps at room temperature. 
1. Dilute blood sample.  Fresh blood and buffy coats should be diluted 1:1 with PBS, 
leukapheresis cones should be diluted with PBS to a final volume of 50 ml. 
2. Layer blood onto lymphoprep at a ratio of 2:1, blood to lymphoprep.  Add 15 ml 
lymphoprep per 50 ml Falcon tube and carefully layer 25 ml diluted blood on top. 
3. Centrifuge at 800 g for 25 min with minimum acceleration and brake. 
4. Remove white buffy layer gently with wide tipped Pasteur pipette.  Combine 2 buffy 
layers into 1 and add PBS to 50 ml. 
5. Centrifuge at 400 g for 10 min. 
6. Discard supernatant and flick tube to loosen pellet.  Combine cell pellets, add PBS to 
50 ml and centrifuge at 300 g for 5 min. 
7. Discard supernatant, re-suspend cell pellet in 50 ml PBS and make a 1 in 10 dilution 
for cell counting.  Count PMBC. 
8. Place the required number of PBMC into a fresh 50 ml Falcon tube, make volume up 
to 50 ml and centrifuge at 300 g for 5 min (see Note 2). 
9. Discard supernatant.  Cells are now ready for selection (see Note 3). 
3.1.2 Preparation of murine bone marrow cells 
1. Dissect out mouse hind legs removing as much muscle as possible and place in 
medium, on ice. 
2. Put bones in 70% ethanol for 1 minute. 
3. Put bones into fresh complete RPMI in 10 cm dish and separate and strip tibias and 
femurs, then remove both ends of the bones with a scalpel. 
4. Transfer into fresh complete RPMI in a new dish and using a 21 G needle and 10 ml 
syringe.  Pull up a few ml of medium and flush the marrow out each of bone into the 
dish. 
5. Transfer cells and medium to a 50 ml Falcon tube and pipette up and down 
repeatedly to dissociate the cells.  Pass through a 40 µm cell strainer into a fresh tube. 
6. Add PBS to a final volume of 50 ml, take an aliquot of cells for counting and 
centrifuge the remainder at 400 g for 5 min, minimum brake (see Note 4). 
7. Discard supernatant.  Cells are now ready for selection. 
3.2 Selection of Immune Cells (monocytes) 
3.2.1 Human monocytes 
1. Re-suspend the PBMC in the required volume of cold MACS buffer according to the 
manufacturer‒sやinstructions and add the appropriate volume of CD14 MicroBeads 
(see Note 5). 
2. Incubate at 4°C for 15 min. 
3. Add 10 ml cold MACS buffer and centrifuge cells at 300 g for 5 min.  Discard the 
supernatant, re-suspend the cells in an appropriate volume of MACS buffer 
according toやtheやmanufacturer‒sやinstructionsやandやadd to a prepared LS column (see 
Note 6). 
4. Apply cell suspension and allow to run through. 
5. Rinse through 3 times with 3 ml MACS buffer. 
6. Add 5 ml of MACS buffer to the column, immediately remove from the magnet and 
flush positive cells out into a fresh 30 ml Universal tube or 15 ml Falcon tube using 
the plunger. 
7. Count CD14 cells.  Verification of cell purity should be carried out by FACS analysis.  
The cells are now ready for loading with reovirus (see Note 7). 
3.2.2 Murine monocytes 
1. Re-suspend cells in 175 µl MACS buffer per 5 x 107 cells. 
2. Add 25 µl FcR blocking reagent and mix well. 
3. Add 50 µl antibody cocktail per 5 x 107 cells, mix well and incubate at 4°C for 5 min. 
4. Add 10 ml MACS buffer per 5 x 107cells and centrifuge at 300 g for 10 min. 
5. Re-suspend cells in 400 µl MACS buffer per 5 x 107 cells, add 100 µl microbeads per 5 
x 107 cells and incubate at 4°C for 10 min. 
6. Apply this solution directly to a prepared LS column and allow to run through. 
7. Rinse through with 3 x 3 ml MACS buffer and collect eluate containing the 
untouched monocytes. 
8. Count the monocytes.  Verification of cell purity should be carried out by FACS 
analysis.  The cells are now ready for loading with reovirus (see Note 8). 
3.3 Loading immune cells with reovirus 
1. Place the required number of immune cells into a 15 ml Falcon tube (see Note 9). 
2. Add 10 ml of PBS to the tube, centrifuge cells at 300 g for 10 min and discard 
supernatant. 
3. Add reovirus at the required multiplicity of infection (MOI) to the cells in the 
residual volume of PBS (see Note 10). 
4. Incubate for 3-4 h at 4°C. 
5. Add 10 ml PBS to the tube, centrifuge at 300 g for 10 min and discard the 
supernatant. 
6. Repeat the PBS wash twice more to ensure complete removal of unbound reovirus. 
7. Gently re-suspend the cell pellet in the required volume of complete RPMI and add 
the loaded carrier cells to the tumour targets (see Note 11). 
8. Monitor tumour cell death. 
3.4 Preparation and loading of reovirus-antibody complexes 
Reovirus-neutralizing antibody complexes (reoNAb) have been generated using (i) whole 
serum from clinical trial patients receiving Reolysin therapy or (ii) reovirus-specific mouse 
monoclonal antibodies(15). 
1. To form the reoNAb complexes, incubate the reovirus with a neutralizing volume of 
the serum/antibody in a 500 µl eppendorf and incubate at 37°C for 2-3 h (see Note 
12). 
2. After incubation, store the reoNAb at 4°C (see Note 13). 
3. ReoNAb loading onto immune cells is performed in exactly the same manner as 
described above for reovirus. 
4. Notes 
1. If the loaded monocytes are to be processed for electron microscopy the use of 
negative selection to isolate untouched monocytes is preferable as this avoids the 
problem of bead debris in the preparation which can produce artefacts in the 
microscopy images. 
2. Estimate the number of PBMC required from the expected frequency of the cell 
subset found within the whole PBMC population e.g. monocytes make up approx. 
10-20% of human PBMC, T cells up to 70% and NK cells 5-10%.  DC are rare (1-2%) 
but myeloid-derived DC can be obtained by culturing isolated monocytes in medium 
containing 800 U/ml human recombinant GM-CSF and 500 U/ml  human 
recombinant IL-4 for 5-6 days.  Anticipate up to 30% cell loss to occur during the 
culture period.  The cells will have an immature DC phenotype and can be used for 
viral loading or matured with a suitable stimulus prior to use.  We routinely loaded 2 
x 106 carrier cells with reovirus for each condition required. 
3. Cell separation is best carried out using fresh samples rather than frozen.  However, 
buffy coats and leukapheresis cones can be stored at room temperature overnight 
prior to PBMC preparation. 
4. Typical count of total BM cells = 4 - 5 x 107 cells per mouse. 
5. For positive selection of monocytes using CD14 MicroBeads, it is possible to obtain 
efficient isolation using only 5 µl of the beads per 107 cells rather than the 
recommended 20 µl.  We have only verified this for Miltenyi CD14 MicroBeads. 
6. 2 LS columns are required per whole buffy coat/leukapheresis cone 
7. If required, isolated cells can be cultured overnight in RPMI/10% FBS/2 mM L-
glutamine prior to loading with virus. 
8. If DC are required the monocytes can be cultured in RPMI complete medium (no 
Pen/Strep) containing 20% L929 conditioned medium as a source of GM-CSF.  The 
cells should be viewed daily and fresh medium added as required.  At day 5 - 6 the 
cells will have an immature DC phenotype.  They can then be used for viral loading 
or matured with a suitable stimulus prior to use. 
9. 15 ml polypropylene Falcon tubes give more efficient retrieval of cells following viral 
loading than 30 ml Universal polystyrene tubes.  Fewer than 2 x 106 cells per tube is 
not recommended as the cell pellet is easily lost during the post-loading wash steps. 
10. MOI ranging from 1-10 with respect to the target cells have been used 
successfully(10, 13, 15).  Coxsackievirus A21 has also been loaded efficiently using 
this protocol(15). 
11. Tumour target cells should be seeded into multi-well plates 24 h prior to the addition 
of the carrier cells.  Routinely 3 x 105 melanoma cells were seeded into wells in 6-well 
plates.  Immediately prior to adding the loaded carrier cells, the medium in the wells 
should be removed and replaced with 2 ml fresh complete medium.  Virus-loaded 
carrier cells were then added at a 4:1, 2:1 or 1:1 ratio, carrier cells to targets, in a 
volume of 500 - 700 µl. 
12. The amount of serum/antibody required should be determined by a standard 
neutralization assay on L929 cells and confirmed by the absence of cell death in 
target cells treated directly with reoNAb.  In general, a reovirus to serum ratio of 1:10 
was used for the formation of reoNAb complexes; this was in excess of the volume 
that was found to be completely neutralizing for all sera tested. 
13. Pre-formed reoNAb complexes can be stored at 4°C for up to 12 h prior to use. 
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